Navigation Links
ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis
Date:9/21/2008

eva Pharmaceutical Industries Ltd.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

Isis Forward-Looking Statement

This press release includes forward-looking statements regarding Isis' business, its drug discovery and development pipeline, and the therapeutic potential of ATL/TV1102 for the treatment of multiple sclerosis. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or pro
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.; Antisense Therapeutics Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015  Seeger Weiss LLP is reporting ... issued a warning letter to C.R. Bard, the manufacturer of ... adequate strides to correct violations the agency found at two ... violations after the FDA cited them during Inspectional Observations that ... Bard,s Tempe, AZ , location and on ...
(Date:7/31/2015)... , July 31, 2015 The ... press release on July 28, 2015, "Surviving Your ... Launches Fundraising for Patient Safety." A ... sentence should read: "PPAHS is a ... Patients on Opioids. For more information on the National ...
(Date:7/31/2015)... Quietly, sedately, Morocco,s pharmaceutical sector is shining. ... is strong, with a well-developed base of local producers ... One place where the quality of Moroccan pharma ... quietly become the second largest African exporter of drugs ... Moroccan pharma companies have been making inroads as exporters ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3
... May 2, 2012 Janssen Research & Development, LLC, ... Drug Applications (sNDAs) to the U.S. Food and Drug ... ® (rivaroxaban), an oral anticoagulant, to treat patients ... and prevention of recurrent venous thromboembolism (VTE). ...
... Official journal of the American Association for ... of scientific, technical and medical information products and services, announces ... American Association for Geriatric Psychiatry (AAGP) to publish ... AJGP ) beginning in January 2013. "We are ...
Cached Medicine Technology:Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 2Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 3Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 4Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 5Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 7Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 8Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry 2Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry 3
(Date:7/31/2015)... , ... July 31, 2015 , ... Ticket Down is ... currently going on in Chicago at Grant Park. The festival will end on ... North America to Chicago for the annual Lollapalooza. This unique and unbelievably popular ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... store run by GoodThreads. The store can be accessed by visiting http://www.curemeso.org/store ... of which are customizable. The best part: whenever a product is purchased, the ...
(Date:7/31/2015)... ... 2015 , ... There’s no better way to enjoy the summer weather than ... the next meal, making July the most appropriate to be National Hot Dog Month. ... , Make the next cookout different than the ones in the past. Celebrate National ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Coco Libre announced ... judges, media, and VIPs at the 2015 Vans US Open of Surfing, July 25 ... that can claim “no added sugar” on the market, is a natural choice given ...
(Date:7/31/2015)... ... 2015 , ... According to the article published July 27 on My News LA, ... and extinguished by the city’s fire department before it caused major damage throughout the building. ... the fire, and it was a fire alarm system that tipped off fire fighters so ...
Breaking Medicine News(10 mins):Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3
... Journal of Human Nutrition and Dietetics assessed whether ... prevention of prostate cancer. Results suggest that a diet low ... vegetables is beneficial in preventing and treating prostate cancer. ... review of dietary recommendations in the prevention of prostate cancer ...
... , Amazing System will Activate More than 6,000 Contacts at 3,000 ... The following is being issued by New America Media: , , WHO: ... Sandy Close , executive director of New America Media (NAM), an organization representing ... Beverly Thomas , vice president of communications and public affairs for ...
... June 3 RESOLVE : The National Infertility ... of New York) last night with The 2009 Friends ... at Tavern on the Green. This awards program recognizes individuals and ... with infertility. This Night of Hope supports RESOLVE in helping the ...
... Key Motivators for Participation , , , ... Company of America (Guardian), a leading provider of employee ... results of a comprehensive survey on consumers, attitudes and ... and high-deductible health plans (HDHPs). , ...
... N.J., June 3 Quest Diagnostics Incorporated (NYSE: ... and services, announced today that, as of 5:00 p.m., New ... Date"), the following principal amounts of its 5.125% Senior Notes ... "Notes") have been validly tendered and not validly withdrawn in ...
... Carolina Care Plan members can now have fresh organic ... homes through a new partnership with The Chef,s Garden, ... South Carolina restaurants including Charleston Grill and Circa 1886. ... eliminate unhealthy habits and promises to enhance diet and ...
Cached Medicine News:Health News:NAM Launches Emergency Network System to Deliver Disaster Alerts and Health Warnings to Millions in Ethnic Communities 2Health News:National Infertility Organization Honors RMA of New York for Community Support 2Health News:Guardian Survey Reveals Widespread Lack of Understanding of Health Savings Accounts 2Health News:Guardian Survey Reveals Widespread Lack of Understanding of Health Savings Accounts 3Health News:Guardian Survey Reveals Widespread Lack of Understanding of Health Savings Accounts 4Health News:Quest Diagnostics Announces Early Tender Results of Offer to Purchase Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes 2Health News:Quest Diagnostics Announces Early Tender Results of Offer to Purchase Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes 3Health News:Carolina Care Plan Launches New Home Delivery Program for Organic Produce 2
... confirmed Atriums superior biocompatibility and strength ... hernia repair. These same studies indicate ... hernia mesh can result in a ... when Atrium first introduced thin wall ...
... Repair Company, we recognize that there are ... tissue in-growth between the prosthesis and the ... Like all the products in Bards complete ... clinically proven, versatile repair.,The Reconix Patch is ...
... In applications such as laparoscopic ... reconstruction, surgeons require a surgical biomaterial ... incorporation.,GORE MYCROMESH Biomaterial provides the answer ... soft tissue reconstructions. Made from strong, ...
... CompanySM is pleased to announce the latest ... Composix E/X mesh.,When Bard Composix mesh was ... ventral hernia repair prosthesis that combined two ... ePTFE, in one product. Bard Composix E/X ...
Medicine Products: